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Abstract
β-hexosaminidase is an enzyme responsible for the degradation of gangliosides, glycans,
and other glycoconjugates containing β-linked hexosamines that enter the lysosome. GM2
gangliosidoses, such as Tay-Sachs and Sandhoff, are lysosomal storage disorders charac-
terized by β-hexosaminidase deficiency and subsequent lysosomal accumulation of its sub-
strate metabolites. These two diseases result in neurodegeneration and early mortality in
children. A significant difference between these two disorders is the accumulation in Sandh-
off disease of soluble oligosaccharide metabolites that derive from N- and O-linked glycans.
In this paper we describe our results from a longitudinal biochemical study of a feline model
of Sandhoff disease and an ovine model of Tay-Sachs disease to investigate the accumula-
tion of GM2/GA2 gangliosides, a secondary biomarker for phospholipidosis, bis-(monoacyl-
glycero)-phosphate, and soluble glycan metabolites in both tissue and fluid samples from
both animal models. While both Sandhoff cats and Tay-Sachs sheep accumulated signifi-
cant amounts of GM2 and GA2 gangliosides compared to age-matched unaffected controls,
the Sandhoff cats having the more severe disease, accumulated larger amounts of ganglio-
sides compared to Tay-Sachs sheep in their occipital lobes. For monitoring glycan metabo-
lites, we developed a quantitative LC/MS assay for one of these free glycans in order to
perform longitudinal analysis. The Sandhoff cats showed significant disease-related
increases in this glycan in brain and in other matrices including urine which may provide a
useful clinical tool for measuring disease severity and therapeutic efficacy. Finally, we
observed age-dependent increasing accumulation for a number of analytes, especially in
Sandhoff cats where glycosphingolipid, phospholipid, and glycan levels showed incremental
increases at later time points without signs of peaking. This large animal natural history
study for Sandhoff and Tay-Sachs is the first of its kind, providing insight into disease pro-
gression at the biochemical level. This report may help in the development and testing of
new therapies to treat these disorders.
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Introduction
β-N-acetylhexosaminidase (Hex) is vital in hydrolyzing and degrading glycoconjugates such as
glycosphingolipids and glycoproteins that enter the lysosome [1–3]. The enzyme acts by cleav-
ing the terminal N-acetylhexosamine (HexNAc), either N-acetylglucosamine (GlcNAc) or N-
acetylgalactosamine (GalNAc) at the non-reducing end of glycoconjugates and their metabo-
lites. Hex is encoded by two genes, HEXA and HEXB. HEXA encodes the α-subunit of the
enzyme, which is directly responsible for hydrolyzing negatively charged substrates due to its
positively charged binding pocket. In contrast, HEXB encodes the β-subunit providing sub-
strates with a negative binding pocket [1, 4, 5]. The enzyme is only functional upon dimeriza-
tion and has three possible isoforms: heterodimer Hex A (αβ), homodimer Hex B (ββ), and
homodimer Hex S (αα) [1, 5]. In humans, Hex A is the sole isozyme responsible for hydrolysis
of GM2 gangliosides [6]. It works in conjunction with a small accessory protein, GM2 activa-
tor protein (GM2AP). GM2AP acts as a cofactor by binding to the carbohydrate and lipid por-
tions of the GM2 ganglioside and presenting the terminal HexNAc to Hex A for hydrolysis [1,
7, 8]. The Hex B homodimer is important as well, degrading other terminal HexNAc-contain-
ing substrates that enter the lysosome. Hex S is thought to have little physiologic relevance; it is
unstable and therefore plays little or no role in degrading substrates [1, 2].
Mutations in either of the HEX genes or the GM2A gene can increase substrate accumula-
tion in patients leading to serious life-threatening disease resulting from the lysosomal accu-
mulation of Hex substrates. These diseases are called GM2 gangliosidoses because of the large
accumulation of GM2 ganglioside in patients which leads to neurotoxicity and demyelination
[1]. Disease onset and severity are influenced by the amount of residual β-hexosaminidase
enzyme activity, which may depend on which gene is mutated and the type of mutation [1, 9,
10]. Depending on which gene is mutated, a patient can be categorized into one of the three
GM2 gangliosidoses.
Tay-Sachs disease is caused by mutations in the HEXA gene, leading to a deficiency in the
α-subunit and consequently the biosynthesis and activity of the Hex A dimer. Hex B is not
affected in Tay-Sachs; therefore, glycosphingolipids accumulate while oligosaccharide sub-
strates continue to be cleared by the action of Hex B [1–3, 10]. Tay-Sachs disease can be further
divided into infantile, juvenile, and late-onset forms depending on the age of symptom onset
(3 to 5 months, 1.5 to 10 years, and older than 10 years, respectively). Patients with the infantile
form experience premature death before the age of 5, and juvenile patients before the age of
15. Patients with the late-onset form experience less severe symptoms including muscle weak-
ness, ataxia, seizures, and slurred speech, but otherwise may have a normal lifespan [2, 11].
Sandhoff disease is caused by mutations in the HEXB gene, resulting in a deficiency in both
Hex A and Hex B enzymes [3]. Because both Hex A and Hex B are affected in this disorder, no
terminal HexNAc-containing substrates are degraded. Sandhoff patients develop symptoms
similar to that of Tay-Sachs and also experience early mortality due to the substrate accumula-
tion [1, 2, 9, 12].
The third type of GM2 gangliosidosis is the AB variant, which is extremely rare and is
caused by a deficiency in the GM2 activator protein, GM2AP [3, 13]. Although Hex A and
Hex B enzymes are functional and remain at normal levels, lack of the activator protein results
in GM2 gangliosides not being presented properly to the Hex A enzyme resulting in the patho-
logical accumulation of gangliosides similar to that observed in Tay-Sachs.
Mutations in any one of these three genes, HEXA, HEXB or GM2A, can cause the accumu-
lation of the GM2 gangliosides and other terminal HexNAc-containing substrates, which
make them relevant biomarkers of disease progression and treatment effects in GM2
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gangliosidosis. Other biomarkers that have been evaluated in GM2 gangliosidoses include gly-
coprotein-derived soluble oligosaccharides, and phospholipids [12, 14, 15].
GM2 gangliosides are glycosphingolipids (GSLs) found abundantly in neurons and
throughout the CNS, but accumulate in GM2 gangliosidosis patients [4, 7]. GSLs are impor-
tant in creating stable synaptic connections for memory formation and overall development of
the brain [4, 7]. GM2 ganglioside accumulation results in significant CNS neuropathology
including inflammation, demyelination, and neurodegeneration. One well documented symp-
tom in patients is the cherry-red spot located in the retina [16]. Ganglioside accumulation can
also lead to secondary insult to the periphery system [1].
Another substrate biomarker class includes soluble oligosaccharide metabolites which are
the products of glycoprotein degradation. The Hex B homodimer plays an important role in
the degradation of both N- and O-linked glycans by cleaving HexNAc at the non-reducing end
of these structures [1]. Free glycans have been found to accumulate in Sandhoff patients, but
not to significant levels in Tay-Sachs patients [1, 17].
A secondary storage material that accumulates alongside terminal HexNAc-containing sub-
strates are lysosomal phospholipids called bis-(monoacylglycero)-phosphate, or BMP phos-
pholipids. BMP phospholipids are responsible for the degradation, recycling, and chaperoning
of molecules into and out of the lysosome [10, 18]. BMP phospholipids have been shown to
increase upon lysosomal stress due to accumulation of incompletely degraded metabolic prod-
ucts, with the most abundant species being di-22:6-bis(monoacylglycerol)phosphate (BMP
(22:6)). BMP(22:6) is a known biomarker for phospholipidosis and is used in assessing pres-
ence or progression of some lysosomal storage diseases [18] including Sandhoff disease [19].
Though the precise pathogenic mechanisms in Sandhoff and Tay-Sachs disease are not fully
understood, disease-related storage material is known to cause grossly distended neurons with
structural abnormalities such as meganeurites (swellings of the axon hillock) and ectopic neur-
ites (small extensions from neuronal processes) [20]. Such defects may contribute to abnormal
neurotransmission or other dysfunction. The accumulation of substrate metabolites is thought
to cause a generalized lysosomal dysfunction leading to the accumulation of secondary sub-
strates (e.g., cholesterol) unrelated to the primary enzyme deficiency [21]. Also, intracellular
signaling cascades and the unfolded protein response may be disrupted by excessive ganglio-
sides, which are thought to participate in signal transduction [22]. In the aggregate, the accu-
mulation of these storage products correlates with cellular pathophysiology and likely plays an
important role in neuronal insult resulting in the profound neurodegeneration observed in
these disorders [23, 24].
A comprehensive natural history study of these metabolic substrates and disease-related
biomarkers has not been done in large animal models for either Sandhoff or Tay-Sachs disease.
These larger animal models are arguably more translatable to humans than are smaller organ-
isms such as rodent models. For example, unlike humans, mice have an alternative catabolic
pathway capable of degrading GM2 ganglioside through the action of Hex B instead of Hex A
[25]. This helps reduce the ganglioside accumulation and may contribute to the less severe
phenotype seen in Tay-Sachs mice compared to affected humans [3, 26]. Large animal models
such as cats and sheep have a brain size and organization more similar to humans than do
mice. Consequently, understanding how these biomarkers behave in large animal models
could lead to a better understanding of patient disease progression at the biochemical level.
Thus, we carried out a natural history study in two large animal models of GM2 gangliosi-
doses, Sandhoff cats and Tay-Sachs sheep. Using liquid chromatography/tandem mass spec-
trometry (LC-MS/MS), we measured levels of gangliosides, BMP(22:6) phospholipid, and free
glycans in tissues and biological fluids from affected animals at different ages over their life
spans.
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Materials and methods
The A2G0 N-glycan was purchased from Prozyme (Hayward, CA). Endoglycosidase Endo S
was purchased from New England Biolabs (Ipswich, MA, USA). Natural abundance aniline
and [13C6] aniline, sodium cyanoborohydride (NaBH3CN), were purchased from Sigma
Aldrich (Milwaukee, WI, USA). Hypersep Hypercarb PGC SPE cartridges (25 mg, 1 mL) and
Pierce BCA Protein Assay Kit were purchased from ThermoFisher Scientific (Waltham, MA,
USA). Creatinine Assay Kit was purchased from Sigma (St. Louis, MO, USA). The ganglioside
standards (GM1, GA1, GM2, GA2 and GM3) were all purchased from Enzo Life Sciences
(Farmingdale, NY, USA) while the BMP(14:0) phospholipid was purchased from Avanti Polar
Lipids (Alabaster, AL, USA). The 10kDa centrifugal filters were from VWR (Radnor, PA,
USA). All other chemicals were of reagent or LC-MS grade for chromatography systems.
Animals and sample collection
Sandhoff cats, Tay-Sachs sheep and species-specific age matched controls were purpose-bred
from the GM2 gangliosidosis research colonies at Auburn University. Cat studies consisted of
9 wild type, 9 affected animals and sheep studies consisted of 8 wild type, 8 affected animals as
indicated in S1 Table. All animal procedures were approved by the Auburn University Institu-
tional Animal Care and Use Committee. All animals were housed, fed, watered and enriched
according to IACUC-approved protocols for GM2 gangliosidosis research colonies at Auburn
University. Animals were monitored at least once daily by interactions with animal care staff,
graduate students and veterinarians on the project. Any welfare concerns were addressed by
the veterinarian investigators on the protocol, the project veterinarian and/or the unit attend-
ing veterinarian. The unit attending veterinarian inspected animals at least once weekly. These
animals were not treated with any experimental therapeutics and simply were monitored
through their disease course until the pre-determined time point for euthanasia.
Cats were group housed in indoor, temperature- and light-controlled wards; were given dry
and wet food from respected vendors; and were enriched by a variety of methods including
trained animal care workers who socialize animals beginning when they are kittens. Cats were
humanely euthanized by first being tranquilized with ketamine (10–20 mg/kg) followed by
intravenous (IV) pentobarbital overdose (100 mg/kg).
Sheep were maintained as a flock in fenced grass pastures that contained shelters from sun
and rain. Their grass diet was supplemented with grain, minerals and hay as needed, and fresh-
water containers were provided. Enrichment included normal flock behavior of sheep (includ-
ing open pastures to graze and run), shearing of wool at least once per summer and daily
interactions with animal care staff and/or project investigators. Sheep were humanely eutha-
nized by first being tranquilized with a combination of midazolam (4mg/kg) and ketamine
(10-20mg/kg) followed by IV pentobarbital overdose (100mg/kg).
Tissue and liquid samples were collected and frozen according to standard methods.
Sandhoff cat samples were obtained from one, two and four-month-old animals, and Tay-
Sachs sheep samples were obtained from three, six and nine-month-old animals. The final
time point coincides with the humane endpoint of each model.
Sample homogenization
Individual brain samples were homogenized in 1 mL of Milli-Q (MQ) water with 2.8 mm
ceramic beads using a Bead Ruptor 24 Homogenizer (Omni International, Kennesaw, GA,
USA) for one cycle of 20 seconds at 4.85 m/s. Protein concentrations for brain, cerebral spinal
fluid (CSF), serum and plasma were determined using a BCA protein assay kit per manufac-
turer’s instructions. Protein concentrations were used to standardize each sample. Creatinine
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concentrations for urine were determined using a creatinine assay kit per manufacturer’s
instructions. Creatinine concentrations were used to normalize urine samples. Homogenized
samples were split for ganglioside and glycan analysis.
Ganglioside and BMP preparation and analysis
Homogenized tissue samples were diluted to 4 μg protein/μL homogenate with MQ water
based on the BCA protein assay results. An amount of sample equal to 200 μg of protein was
extracted with 500 μL 95/5 methanol/glacial acetic acid (v/v). Extracts were filtered through 10
kDa centrifugal filter and clarified samples were injected into the LC-MS/MS or stored at 20˚C
until further use. The five different gangliosides and BMP(22:6) were analyzed in each sample
with an Acquity UPLC and Xevo TQ-S Micro Triple Quadrupole Mass Spectrometer (Waters
Corporation, Milford, MA, USA).
The gangliosides were separated using an Acquity UPLC Glycan BEH Amide column
(Waters Corporation, Milford, MA, USA). Mobile phase A consisted of 5 mM ammonium ace-
tate in 94.5% acetonitrile, 2.5% methanol, 2.5% MQ water, with 0.5% formic acid, and mobile
phase B consisted of 100% MQ water. The column temperature was set at 50˚C and a flow rate
of 0.4 mL/min. Sample injection volume was 2 μL. Samples were ionized in positive ion mode
by ESI with the capillary voltage set at 1.0 kV, the desolvation temperature set at 500˚C, and a
desolvation gas flow of 1000 L/hr. The samples were eluted using a concentration gradient of
95% A/5% B for two minutes, increase to 50% A/50% B over 10 minutes, holding there for
another 10 minutes, and finish at 95% A/5% B for the last four minutes. Samples were quanti-
fied based on a five-point standard curve (100–6.25 pg/μL) of GM1, GA1, GM2, GA2, and
GM3 gangliosides. The sum of two parent-product ion transitions for each ganglioside
(Table 1) was used for quantitation [27].
For BMP(22:6), samples were separated on an Acquity UPLC HSS C18 column (Waters
Corporation, Milford, MA, USA). Mobile phase A consisted of 5 mM ammonium formate in
74% methanol, 25% MQ water, and 1% formic acid, and mobile phase B consisted of 5 mM
ammonium formate in 99% methanol and 1% formic acid. The column temperature was set at
50˚C with a 5 μL injection volume at a flow rate of 0.1 mL/min. Samples were ionized in nega-
tive ion mode by ESI with the capillary voltage set at 3.5 kV, desolvation temperature set at
600˚C, and the desolvation gas flow at 1000 L/hr. The samples were eluted using a concentra-
tion gradient starting at 80% A/20% B for one minute, ramping to 100% B over five minutes,
holding for 10 minutes, followed with 80% A/20% B for the last four minutes. A five point
standard curve (100–6.25 pg/μL) of BMP(14:0) was prepared and BMP(22:6) concentrations
are reported as equivalents of BMP 14:0. One precursor to product ion transition was moni-
tored for each BMP species (Table 2).
Glycan sample preparation
Homogenized and clarified tissue samples were diluted to 240 μg of protein in 1 mL of MQ
water. Next, Hypersep Hypercarbon PGC were prepared by first washing three times with 1
mL of 80% acetonitrile with 0.1% TFA, followed by three times with 1 mL of MQ water. The
diluted samples were applied to the column and the flow through was discarded. Columns
were washed three times with 1 mL of MQ water, then placed over a 15 mL centrifuge tube.
Free glycans were eluted with three 1 mL aliquots of 30% acetonitrile with 0.1% TFA. The col-
lected free glycans were dried down in a SpeedVac overnight.
Dried free glycan metabolites were labeled by reductive amination by first reconstituting
them with 17 μL of aniline, mixing 10–15 times. Next, 17 μL of freshly prepared 1 M
NaCNBH3 in 70% DMSO and 30% glacial acetic acid was added to each sample and again
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mixed 10–15 times, then incubated overnight at 37˚C. The labeled samples were dried in a
SpeedVac overnight.
Prior to analysis by LC/MS, the labeled samples were reconstituted with 150 μL MQ water.
30 μL of each sample was placed into a mass spectrometry vial with 5 μL of [13C6] aniline
tagged internal standard (A2G00) and dried in a SpeedVac for one hour. The dried sample and
internal standard were then reconstituted in 20 μl 78% acetonitrile and 22% 100 mM ammo-
nium formate pH 4.5 for analysis.
Internal standard preparation
In order to generate the A2G00 hexasaccharide standard, it was necessary to first cleave off the
reducing end GlcNAc residue from the fully intact A2G0 heptasaccharide. The A2G0 glycan
(2000 pmoles) was digested with Endo S (800 units) in a total volume of 20 μL of 50 mM
Sodium Phosphate pH 7.5 for 18–24 hours followed by purification on a Sep-PAK C18 SPE
cartridge (100 mg, 1 mL), as to the manufacturer’s instructions, and dried by centrifugal evap-
oration. The dried resulting A2G00 (A2G0 prime) glycan standard was then labeled with 13C6-
aniline (15 μL, 15 μL 1 M NaCNBH3 in 70:30 DMSO:HOAc) at 37˚C for 18–24 h and the
remaining 13C6-aniline was removed by centrifugal evaporation. Prior to analysis, the internal
standard was dissolved in water.
LC/MS analysis and quantitation of A2G00
LC/MS analysis was performed on an Acquity UPLC system equipped with a Glycan BEH
Amide HILIC column (1.7 μm, 2.1 mm x 150 mm) (Waters, Milford, MA, USA) connected to
a Thermo LTQ Orbitrap XL mass spectrometer. Solvent A was 100 mM Ammonium Formate
pH 4.5 and Solvent B was Acetonitrile with an initial composition of 22% A/78% B and a flow
rate of 0.2 mL/min. The column temperature was kept at 60˚C. Prior to injection an amount
of aniline labeled sample equal to 70 μg of protein, for tissues, or 20 μL, for urine, was placed
in a LC/MS sample vial along with 10 pmoles of 13C6-aniline labeled A2G0
0 biomarker internal
standard and dried by centrifugal evaporation. The samples were then dissolved in a solution
of 22% A/78% B. The labeled free glycans were eluted using a gradient profile of 22% A/78% B
Table 1. Retention times for each analyte of interest.
Analyte Species Precursor Ion Product Ion Cone (V) Collision Energy (V) Approx. Retention Time (min)
GM1 GM1(36:1) 1546.7 366.1 10 36 7.2
GM1(38:1) 1574.7 366.1 10 36
GA1 GA1(36:1) 1255.7 366.1 10 24 6.6
GA1(38:1) 1283.8 366.1 10 24
GM2 GM2(36:1) 1384.7 204.1 10 44 6.6
GM2(38:1) 1412.7 204.1 10 44
GA2 GA2(36:1) 1093.6 264.3 10 54 5.3
GA2(38:1) 1121.6 292.3 10 54
GM3 GM3(36:1) 1181.5 264.3 10 54 6.1
https://doi.org/10.1371/journal.pone.0243006.t001
Table 2. Retention times for each analyte of interest.
Analyte Precursor Ion Product Ion Cone (V) Collision Energy (V) Approximate retention Time (min)
BMP(14:0) 665.4 227.2 10 32 7.5
BMP(22:6) 865.5 327.3 10 32 7.5
https://doi.org/10.1371/journal.pone.0243006.t002
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to 37% A/63% B over 65 min, 100% A/0% B for 6 min, 100% A/0% B to 22% A/78% B in 5 min
and held there for 9 min.
The LTQ Orbitrap XL was operated in the positive ion mode and the sample introduced by
ESI. The capillary temperature was set at 250˚C with a spray voltage of 2 kV. The sheath gas
flow was set to 58 and the auxiliary gas flow to 9. Full scans were performed at a resolution of
60,000 and a range of 200–2250 m/z. Data-dependent collision induced dissociation (CID)
was performed on the three most intense ions in the full scan using a normalized collision
energy of 35 V and an activation time of 30 ms. The N-glycan A2G00 metabolite was deter-
mined by ratio-metric comparison of the 12C6-aniline labeled endogenous A2G0
0 ion abun-
dance with that of the known molar amount of the internal standard spike as previously
described [28].
Statistical analysis
Statistical analyses were performed using R software (version 3.6.3, R Foundation for Statistical
Computing, Vienna, Austria [29]). All data points were included in the analyses with no outli-
ers excluded. For comparing analyte differences between affected and unaffected animals at
each time point, one-tailed, unpaired Student’s t test was used. For comparing analyte levels at
different time points within groups, two-way ANOVA followed by Tukey correction was per-
formed. For correlations between ganglioside and A2G00 levels, a Pearson correlation test was
used. All data are expressed as mean ± SD throughout the text and figures.
Results
CNS accumulation of gangliosides in a cat model of Sandhoff disease
For our hexosaminidase β-subunit deficiency longitudinal study, we used a feline model of
Sandhoff disease with a spontaneous mutation in the HEXB gene [30]. Residual hexosamini-
dase activity in this model was previously measured at approximately 1% of normal on average
across the entire brain and less than 1% of normal in the occipital lobe [31]. Age-matched
unaffected normal control cats were used for comparison to Sandhoff cats at ages of one, two
and four months (the humane endpoint) for substrate accumulation analysis. Single brain
punch samples taken from the occipital lobe of each cat were homogenized, lipid extracted
with acidified methanol and gangliosides quantified using LC-MS/MS analysis as described in
the Method section. We measured the levels of two GM2 ganglioside isomer species, GM2
(36:1) and GM2 (38:1) which are known to accumulate in HEXB null mice [19, 27, 32] and
human patients [12, 33]. We also measured levels of GM1 and GM3 gangliosides as well as the
corresponding asialo species for GM1 and GM2 (GA1 and GA2).
Our results for the occipital lobe showed GM1 gangliosides were at similar baseline levels
(between 7.1 and 10.6 ng GM1/μg protein) across all the wild type and Sandhoff cat CNS sam-
ples (Fig 1 and S2 Table). Little to no GA1 or GM3 gangliosides were detected in either
affected or unaffected samples. In sharp contrast, GM2 ganglioside levels in the one-month-
old Sandhoff cats were greatly elevated nearly 250-fold compared to age-matched normal con-
trols (0.17 vs 38.2 ng GM2/μg protein, Fig 1 and S2 Table). The corresponding asialo GA2
gangliosides were detected in the one month old controls at very low levels (0.02 ng GA2/μg
protein) but were detected at elevated levels (4.3 ng GA2/μg protein) in the age-matched
affected felines (Fig 1 and S2 Table). Like the increase seen with GM2, this also constitutes a
nearly 250-fold increase in detectable levels related to disease. Furthermore, unlike what we
observed for the age matched normal controls, the levels of both GM2 and GA2 gangliosides
were detected at higher levels at later time points consistent with levels continuing to rise in
affected animals as they advance in age (Fig 1 and S2 Table). GM2 levels increased from 38.2
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ng GM2/μg protein to 88.2 ng GM2/μg protein by two months of age and then increased again
to 122.9 ng GM2/μg protein by the last time point at four months. GA2 levels increased from
4.3 ng GA2/μg protein to 6.6 ng GA2/μg protein by two months of age and then again to 14.7
ng GA2/μg protein by four months. ANOVA analysis showed these progressive increases to be
significant (Fig 1 and S3 Table) and the measured trends showed no signs of slowing down.
Since we did not observe a drop in the rate of substrate accumulation by the last time point
tested, these results may have implications for the severity of disease as affected animals con-
tinue to age and accumulate a greater ganglioside burden.
CNS accumulation of BMP phospholipids in a feline model of Sandhoff
disease
After measuring ganglioside levels in occipital lobe samples taken from normal control and
affected cats, we analyzed these samples for the secondary phospholipid biomarker BMP (22:6)
previously shown to be elevated in Sandhoff disease [19]. As expected, BMP(22:6) was found
at elevated levels in affected animals compared to age matched normal controls which exhib-
ited little to no BMP(22:6) (Fig 2 and S2 Table). At the one month time point, no BMP(22:6)
was detected in the age-matched control while 133.3 ng BMP(22:6)/mg protein was detected
in the affected cats. These phospholipid levels increased slightly to 163.3 ng BMP(22:6)/mg
protein by the two month time point but this increase over that detected at one month was not
significant (Fig 2, S2 and S3 Tables). Levels increased further to 283.3 ng/mg protein by the
four-month time point. The increase in BMP(22:6) between the two earlier time points and
Fig 1. Feline Sandhoff brain ganglioside levels. Ganglioside levels were measured in Sandhoff (SH) and age-matched unaffected (UA) cats. Samples from biopsied
occipital lobe taken from animals 1, 2, and 4 months old (mo) were analyzed and the mean results for each time point (n = 3) are shown as ng Ganglioside/μg protein
equivalents. Error bars represent ± SD. The degree of significant difference between age-matched UA and SH felines is indicated by the number of asterisks above each
bar for GM2 and GA2 (��� p� 0.001, �� p� 0.01, � p� 0.05). Square brackets with asterisks above GM2 bars indicate the significant difference in GM2 levels between
time points for affected cats.
https://doi.org/10.1371/journal.pone.0243006.g001
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the last was significant (S3 Table) demonstrating that, like GM2 and GA2 gangliosides, BMP
(22:6) phospholipid levels in the brain follow an increasing trend with age. We also saw no
signs of this trend slowing down by the last time point tested similar to the age dependent
accumulation seen for GM2 and GA2 gangliosides in these affected animals (Fig 1). Thus,
Sandhoff cats are subjected to an increasing burden of both gangliosides and BMP phospholip-
ids over time which may have a significant impact on disease severity as these animals get
older.
Accumulation of hexosaminidase substrate oligosaccharide metabolites in
a feline model of Sandhoff disease
The β-subunit of hexosaminidase is important for the degradation of both gangliosides and
other glycoconjugates such as proteoglycans and glycoproteins [34, 35]. Thus, Hex B
Fig 2. Feline Sandhoff brain BMP(22:6) levels. BMP phospholipid levels were measured in Sandhoff (SH) and age-matched unaffected (UA) cats. Samples from
biopsied occipital lobe taken from animals 1, 2, and 4 months old (mo) were analyzed and the mean results for each time point (n = 3) are shown as ng BMP(14:0)
phospholipid equivalent/mg protein equivalents. Error bars represent ± SD. The degree of significant difference between age-matched UA and SH felines is indicated
by the number of asterisks above each bar (��� p� 0.001, �� p� 0.01, � p� 0.05). Square brackets with asterisks above bars indicate significant difference in BMP
(22:6) levels between time points for affected cats.
https://doi.org/10.1371/journal.pone.0243006.g002
PLOS ONE Glycan accumulation in large animal models of GM2 gangliosidoses
PLOS ONE | https://doi.org/10.1371/journal.pone.0243006 December 1, 2020 9 / 25
deficiency leads to the accumulation of multiple substrate metabolites including soluble oligo-
saccharides as has been observed in a number of previous studies [14, 36–39].
In order to detect these types of metabolites in the feline CNS, we used a method we previ-
ously employed to detect and characterize similar limit digestion products in another related
disease, GM1 Gangliosidosis [27]. Soluble free glycans present in water homogenates made
from occipital lobe samples were end-labeled with aniline by reductive amination, separated
by forward phase chromatography on an amide column and labeled glycans were detected by
mass spectrometry as described in the Methods section. Based on the m/z values of intact
molecular ions and data dependent product ion analysis, a number of glycan metabolites were
detected in one-month old Sandhoff cat brains while little to no glycans were detected in age-
matched unaffected normal controls (Fig 3). We saw similar results at all time points tested
with large amounts observed in all affected animals and no significant signal detected in age-
matched normal controls. Based on the Hex B deficiency in affected felines, these glycan
metabolites should have in common HexNAc at their non-reducing ends consistent with their
being limit digestion products. This was verified on the mass spectrometer for many of these
species by product ion analysis after data dependent collision induced dissociation (CID) (see
example in Fig 3). Product ions consistent with the neutral loss of HexNAc from the non-
reducing end allowed us to assign putative structures to many of these species (Fig 3B). One of
these glycan metabolites is a hexasaccharide with a m/z value (1191.47) consistent with an ani-
line labeled metabolite derived from the bi-antennary complex N-glycan GlcNAc-Man-
(GlcNAc-Man)-Man-GlcNAc-GlcNAc (A2G0, Oxford notation). This metabolite (see Fig 3B)
differs from the parent glycan by the loss of the reducing-end GlcNAc residue which occurs
before the β-hexosaminidase catalyzed step in the catabolic pathway for N-linked glycan deg-
radation and is therefore not affected by Hex A/B deficiency [40]. For clarity, this metabolite is
referred to in this paper as A2G00 (A2G0 prime). A standard for this metabolite, useful for its
quantitation by glycan reductive isotope labeling LC-MS (GRIL-LC/MS) [28], can be prepared
from commercially available A2G0 by enzymatic cleavage of the reducing end GlcNAc and
subsequent differential isotope labeling with aniline as described in the Methods section. For
quantitation, we spiked a known molar amount of [13C6] aniline-labeled A2G0
0 internal stan-
dard into each sample after labeling the free glycans in them with [12C6] aniline. The quantity
of A2G00 in the sample was determined by comparing the ion intensity of endogenous A2G00
with that of the internal standard. Brain homogenates, CSF, plasma, and urine samples from
both affected and age-matched unaffected control animals were analyzed for this free glycan as
described in the Methods section.
Our analysis of A2G00 in both affected and unaffected Occipital lobe samples showed no
detectable signal for this analyte in normal controls at all time points tested while affected ani-
mals exhibited large amounts of A2G00 (Fig 4A and S2 Table). At the one-month time point,
A2G00 levels were 134.2 ng/mg protein with levels not significantly changing by the two-
month time point (129.8 ng/mg protein). However, by the last time point at four months,
A2G00 levels had increased to 261.2 ng/mg protein, a two fold increase from the levels seen at
the earlier time points (Fig 4A and S3 Table). Thus, we observed evidence for an age-related
increase for this glycan metabolite in affected brain samples consistent with what we found for
the other analytes we tested. Also, because we were unable to detect A2G00 in any of the age-
matched normal controls, this metabolite is a good candidate for a Sandhoff disease-related
biomarker in the brain, similar to other β-hexosaminidase substrates such as GM2 and GA2
gangliosides.
The pattern of disease-related accumulation for A2G00, showing no significant changes in
accumulation between the first and second time points but a significant increase seen by the
last time point, is similar to that of GA2 gangliosides and BMP(22:6) phospholipid, suggesting
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similar rates of increase for these three analytes. The pattern of increase for GM2 gangliosides
differed from this trend by showing a significant increase by the intermediate time point in
affected animals. While the pattern of increase may differ among some of the analytes tested,
they all showed the same trend of increasing with age in affected cats. When we compared the
increasing trends for gangliosides and A2G00, we observed good positive correlations between
A2G00 and both GM2 and GA2 ganglioside levels in the occipital lobe of the affected animals
Fig 3. Soluble oligosaccharide metabolites in Sandhoff and unaffected cat brains. The soluble fraction from water homogenates made from occipital lobe samples
collected from both wild type and Sandhoff cats at one month of age was end-labeled with aniline as described in the Methods section in order to detect the presence of
reducing sugar metabolites. Labeled products were analyzed by LC/MS with molecular species determined to be oligosaccharides by data-dependent product ion
analysis. The results for both wild type and affected cats are presented at the same ion intensity scale (Relative Abundance) with the column retention time indicated on
the x axis. (A) Extracted ion current for free glycans in one-month old normal unaffected control feline occipital lobe showing little or no detection of soluble
oligosaccharides. (B) Extracted ion current for free glycans in a one-month old Sandhoff cat occipital lobe showing a number of soluble glycans with their corresponding
m/z values above each peak or set of isobaric peaks (indicated by a solid line above). Putative structures based on m/z values and product ion analysis by CID to detect
species with terminal HexNAc residues are also shown. The quantifiable hexasaccharide species with m/z = 1191.47, A2G00 is indicated above the peak eluting at
approximately 33 minutes. (C) Data-dependent product ion profile for the putative A2G00 ion eluting at approximately 33 minutes. The major product ions are shown
along with their m/z values which are consistent with the structures shown. Arrows between the product ions illustrate the inter-ring cleavage loss of neutral
monosaccharide fragments leading to the generation of subsequently smaller product ions. For example, the product ion with m/z value of 988.50 was formed by the
neutral loss of a HexNAc residue by the parent ion from its nonreducing end. Monosaccharides are shown symbolically as follows: glucose (blue circles), galactose
(yellow circles), mannose (green circles), N-acetylglucosamine (blue squares), and N-acetylgalactosamine (yellow squares).
https://doi.org/10.1371/journal.pone.0243006.g003
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(Fig 5). In addition to exhibiting age-related increases, none of the analytes showed signs of
reaching a plateau suggesting that these pathologically relevant molecules can continue to
accumulate, possibly increasing the severity of the disease as the animals mature.
We next analyzed a series of fluid samples, collected from the same animals that the brain
samples were taken from, which included cerebral spinal fluid (CSF), plasma, and urine sam-
ples. Since analyzing gangliosides and phospholipids in these liquid matrices is challenging, we
focused our attention on measuring A2G00 levels which we reasoned would be easier to detect
because of its soluble nature. As was true for the occipital lobe, we were unable to detect A2G00
in any of the CSF samples collected from normal controls at any of the time points tested.
However, we detected A2G00 in affected cats with 1.0 ng/mg protein detected at 1 month of
age increasing to 3.2 ng/mg protein by 4 months of age (Fig 4B and S2 Table). While the
Fig 4. Feline Sandhoff A2G00 glycan metabolite levels. Samples from Sandhoff (SH) and unaffected (UA) age-matched cats 1, 2, and 4 months old (mo) were analyzed
with the mean results shown for each time point (n = 3) as ng A2G00/mg protein equivalents or ng A2G00/mL sample. Error bars represent ± SD. The degree of
significant difference between age-matched UA and SH felines is indicated by the number of asterisks above each bar (��� p� 0.001, �� p� 0.01, � p� 0.05). Square
brackets with asterisks above bars indicate significant difference in A2G00 levels between time points. (A) Mean glycan levels in occipital lobe. (B) Mean glycan levels in
cerebral spinal fluid (CSF). (C) Mean glycan levels in plasma. (D) Mean glycan levels in urine (not normalized to creatinine).
https://doi.org/10.1371/journal.pone.0243006.g004
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trend in mean values suggests a linear increase with age, there was no significant differences in
these levels (S3 Table). Thus, the levels of accumulation in CSF appeared to have largely pla-
teaued by the first time point. The results for plasma were similar to those for CSF (Fig 4C and
S2 Table). Again, none of the age-matched normal controls exhibited A2G00 while all of the
affected animals had detectable levels, albeit, at generally lower levels than those seen in CSF.
Levels ranged from 0.42 ng/mg protein at 1 month to 0.52 ng/mg protein by 4 months, though
this marginal increase was not significant (S3 Table). The results for urine differed from the
results for the other matrices primarily because of the unaffected controls which exhibited
measurable levels of A2G00 (Fig 4D and S2 Table). At the one-month time point, A2G00 was
measured in normal control cats at 4.7 ng/mL urine. This level increased to 19.5 ng/mL urine
by the terminal time point in the unaffected animals. It is important to note that the urine sam-
ples were not normalized to creatinine and therefore measurements were not adjusted for pos-
sible variations in urine concentration. In contrast, levels were much higher in affected cats.
For example, urine A2G00 levels at the earliest time point were measured at 2726.2 ng/mL
urine, an over 500-fold increase compared to age-matched normal cats. As with plasma, we
saw no significant increase in glycan metabolite levels at the later time points (S3 Table). Thus,
all the liquid matrices differed from brain tissue by having plateaued by the one-month time
point in affected animals. This suggests that in affected tissues, such as the occipital lobe, that
A2G00 is continuing to accumulate as animals age but the levels in biological fluids are in equi-
librium between the cellular processes that route excess A2G00 into these fluids and the elimi-
natory systems that remove it from the body.
Our results show that the levels of GM2 gangliosides and soluble oligosaccharide metabo-
lites such as A2G00 in a large animal model of Sandhoff disease correlate well with this disor-
der. Glycans in Sandhoff patients have been characterized in past research [38, 41], but this is
the first account of quantitatively measuring free glycan metabolites in urine from cats with
Sandhoff disease. While, the A2G00 metabolite was detectable in all four matrices tested, its
abundance in urine collected from affected animals suggests that it could be useful as a non-
Fig 5. Correlation between A2G00 and GM2/GA2 ganglioside accumulation. The data from Figs 1 and 4 for brain (occipital lobe) homogenate levels of GM2 and GA2
gangliosides and A2G00 glycan metabolite are plotted against each other showing a good positive correlation between each ganglioside and the free glycan. Both the
Pearson correlation coefficient (r) and p value (p) are shown. The data for all time points: 1 month of age (blue), 2 months of age (green) and 4 months of age (red) for
affected animals and all age matched unaffected normal animals (black) are shown. (A) Correlation between GM2 ganglioside and A2G00 glycan levels in brain
homogenates. (B) Correlation between GA2 ganglioside and A2G00 glycan levels in brain homogenates.
https://doi.org/10.1371/journal.pone.0243006.g005
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invasive clinical biomarker comparable to gangliosides which are harder to access outside of
the brain. In fact, we observed good positive correlations between A2G00 and both GM2 and
GA2 ganglioside levels in the brains of the affected animals used in this study.
CNS accumulation of gangliosides in an ovine model of Tay-Sachs disease
Tay-Sachs sheep have a naturally occurring spontaneous mutation in the HEXA gene [3, 42].
Residual HexA activity in this model organism was previously measured at approximately 8%
of normal across the entire brain and 7% of normal in the occipital lobe [43]. Age-matched
unaffected normal control sheep were used to compare to Tay-Sachs sheep at three, six and
nine months of age for substrate and phospholipid accumulation analysis. The final time point
corresponds to the humane endpoint for Tay-Sachs sheep.
GM2 and GA2 ganglioside analysis was performed and evaluated just as we did for the
Sandhoff cat model in this study. However, unlike for the Sandhoff cats where we only ana-
lyzed occipital lobe samples, we analyzed biopsy samples from seven different brain regions in
the Tay-Sachs sheep. These regions included two cerebellum samples, a single sample from the
corona radiata, the thalamus and three cerebral cortical regions (occipital, temporal, and parie-
tal). The samples were frozen and later homogenized, the gangliosides were extracted, and LC/
MS/MS was used for quantification. The data for the individual regions were then combined
to give the total brain result.
Similar to our results with Sandhoff cats, our results with Tay-Sachs sheep showed little to
no effects on GM1, GA1 and GM3 ganglioside levels for total brain (Fig 6). On the other hand,
GM2 and GA2 ganglioside levels showed significant increases comparing affected animals to
age-matched normal controls (Fig 6 and S4 Table), a trend that was observed in all regions
tested (S1 Fig). In three-month old normal controls, we detected 0.50 ng GM2/μg protein but
in age-matched affected sheep we detected greater than tenfold higher levels (5.44 ng GM2/μg
protein). By the last time point, the difference between controls and affected animals was hun-
dreds of time greater (0.009 ng GM2/μg protein and 15.6 ng GM2/μg protein, respectively)
(Fig 6 and S4 Table). We did not observe a significant difference in GM2 levels between the
three- and six-month time points in affected sheep (S5 Table) and unfortunately, we only had
two animals in each genotypic group at the nine month time point. Thus, we were not able to
conclusively determine if there was an age-related increase in GM2 levels in affected sheep as
we saw with Sandhoff cats. Regardless, the higher mean value at the last time point does sug-
gest that such an increasing trend may exist for Tay-Sachs sheep as well. Results for GA2 gan-
gliosides exhibited significant levels of increase at all time points analyzed (Fig 6 and S4
Table) compared to age-matched controls and also showed significant age-related increases in
affected sheep across the ages tested (S5 Table). Since the final time point showed the highest
levels of both GM2 and GA2, brain levels appear to be continuing to increase with age, leading
to a progressive substrate burden as Tay-Sachs sheep get older.
While all of the 7 regions tested from affected animals showed large relative increases in
GM2/GA2 levels compared to age-matched normal controls, the trends due to age showed
some distinct patterns (S1 Fig). Since we analyzed only the occipital lobe in the Sandhoff cat,
we compared the results for occipital lobe from Sandhoff cats to those of Tay-Sachs sheep. The
observed GM2 levels were approximately 18-fold less in Tay-Sachs sheep than those measured
in the feline Sandhoff occipital lobe (S2 Fig). Likewise, we detected 9-fold less GA2 in Tay-
Sachs sheep occipital lobe compared to Sandhoff cats. The difference in these levels may be
attributed to the variation of ganglioside accumulation across species or differences in residual
enzyme activity seen in these animal models (Sandhoff cats have < 1% normal levels and Tay
Sachs sheep have relatively higher < 8% normal levels) [3, 30, 42]. Regardless, our results for
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both disease models demonstrate a progressive trend for the accumulation of these ganglio-
sides in the brain.
CNS accumulation of BMP phospholipids in an ovine model of Tay-Sachs
disease
Similar to what we observed in the feline Sandhoff model, we detected an elevation in BMP
phospholipid levels in the diseased sheep brain compared to the normal controls (Fig 7 and S4
Table). The unaffected animals showed low levels of BMP(22:6), but the three month old Tay-
Sachs sheep exhibited large increases (29.9 ng BMP(22:6)/mg protein and 528.3 ng BMP(22:6)
in unaffected and affected sheep, respectively). There was no significant further increase of
BMP phospholipid observed at later time points suggesting that levels had peaked by 3 months
of age (S5 Table). Similar to what we observed for ganglioside levels, the BMP phospholipid
profiles showed differences among the 7 regions tested in Tay-Sachs sheep (S3 Fig). However,
unlike the big differences in the levels of accumulation we saw in the occipital lobe of Sandhoff
cats and Tay-Sachs sheep for GM2 and GA2 levels, the occipital lobe BMP(22:6) levels were
comparable between these two models (S2B Fig). Interestingly, unlike in Sandhoff cats, we
saw no increase in accumulation over time. This may be due to species differences or the time
points chosen. We saw a significant increase in feline BMP(22:6) levels between the two and
four month time points. Our earliest time point for ovines was three months. It is possible that
BMP(22:6) may have peaked by then in the felines as well.
Fig 6. Ovine Tay-Sachs brain ganglioside levels. Tissue samples from seven different brain regions from Tay-Sachs (TS) and age-matched unaffected (UA) normal
control sheep were collected at three different ages: 3, 6 (n = 3), and 9 months old (n = 2) and ganglioside levels measured by LC/MS/MS. The seven regions analyzed
included two different samples from cerebellum and single biopsies from corona radiata, thalamus, occipital lobe, temporal lobe, and parietal lobe. The mean (± SD) for
each set of animals for each age tested corresponding to the cumulative results from the seven different brain regions, normalized to amount protein is shown.
Ganglioside levels at each time point are shown as ng ganglioside/μg protein equivalents. Error bars represent ± SD. The degree of significant difference between age-
matched UA and TS sheep is indicated by the number of asterisks above each bar for GM2 and GA2 for TS sheep (��� p� 0.001, �� p� 0.01, � p� 0.05).
https://doi.org/10.1371/journal.pone.0243006.g006
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Effects on oligosaccharide metabolites in an ovine model of Tay-Sachs
disease
In Tay-Sachs sheep, the HEXA mutation only affects the production of the Hex A isozyme,
leaving the Hex B homodimer largely unaffected [3, 42, 44]. With fully functional Hex B, the
Tay-Sachs model should be able to effectively degrade oligosaccharide metabolites that enter
the lysosome. Therefore, no significant accumulation of the kind of oligosaccharides present
in Sandhoff disease are expected in the ovine Tay-Sachs model.
We checked Tay-Sachs sheep for the presence of accumulating glycan metabolites and
found only very low levels compared to those we detected in Sandhoff cats (S4 Fig). We
detected no significant accumulation of the A2G00 N-glycan metabolite in any of the brain
samples we analyzed except for the last time point which showed about a 10-fold increase com-
pared to age-matched unaffected controls (Fig 8A and S4 Table). In comparing the amounts
Fig 7. Ovine Tay-Sachs brain BMP phospholipid levels. Tissue samples from seven different brain regions from Tay-Sachs (TS) and age-matched unaffected (UA)
normal control sheep were collected at three different ages: 3, 6 (n = 3), and 9 months old (n = 2) and BMP(22:6) levels measured by LC/MS/MS. The seven regions
analyzed included two different samples from cerebellum and single biopsies from corona radiata, thalamus, occipital lobe, temporal lobe, and parietal lobe. The mean (±
SD) for each set of three animals for each age tested corresponding to the cumulative results from the seven different brain regions, normalized to amount protein is
shown. The mean results for each time point are shown as ng BMP(14:0) phospholipid equivalents/mg protein equivalents. Error bars represent ± SD. The degree of
significant difference between age-matched UA and TS sheep is indicated by the number of asterisks above each TS bar (��� p� 0.001, �� p� 0.01, � p� 0.05).
https://doi.org/10.1371/journal.pone.0243006.g007
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accumulating in the occipital lobe of Sandhoff and Tay-Sachs animals, A2G00 levels were far
higher in Sandhoff cats (261.2 ng compared to 3.1 A2G00/mg protein). As we did for ganglio-
sides, we tested the same seven regions of the brain, including the occipital lobe. As with the
occipital lobe, we did see signs of modest accumulation in some of these other regions includ-
ing the corona radiate, parietal, temporal, and the thalamus (S5 Fig). Similar to the occipital
lobe, these increases were significant only at the nine-month time point.
As we did with Sandhoff cats, we also analyzed A2G00 levels in CSF, urine and, for sheep,
instead of plasma we analyzed serum (Fig 8). No significant amounts were detected in CSF
Fig 8. Ovine Tay-Sachs A2G00 glycan metabolite levels. A2G00 levels in Tay-Sachs (TS) and age-matched unaffected (UA) normal control sheep were measured in
different sample matrices at 3, 6 (n = 3, unless otherwise indicated), and 9 months of age (n = 2, unless otherwise indicated). Where levels were detected, the mean
results ± SD for each time point are shown as ng A2G00/mg protein equivalents or ng A2G00/mL sample. Error bars represent ± SD. The degree of significant difference
between age-matched UA and TS sheep is indicated by the number of asterisks above each TS bar (��� p� 0.001, �� p� 0.01, � p� 0.05). For comparison, results were
scaled to the same scales (y-axes) used for the Sandhoff cats. (A) The cumulative A2G00 levels from seven different brain regions including cerebellum, corona radiata,
thalamus, occipital lobe, temporal lobe, and parietal lobe, normalized to amount protein. (B) CSF A2G00 levels. (C) Serum A2G00 levels. Six-month TS serum samples
were collected n = 2. (D) Urine A2G00 levels scaled to Sandhoff levels and without creatinine normalization. The six-month TS urine was collected n = 2 and no nine-
month UA urine was collected.
https://doi.org/10.1371/journal.pone.0243006.g008
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and serum collected from Tay-Sachs sheep at any of the time points tested (Fig 8B and 8C).
Similar to the normal control cats that we compared to Sandhoff cats, urine from age-matched
unaffected sheep exhibited only small measurable amounts of A2G00 which were not per-
turbed by disease. There was no significant increase due to Hex A deficiency and no age-
related increases were detected. What’s more, the urinary levels detected in both unaffected
and affected sheep were similar to the normal range seen in normal cats (compare S2 and S4
Tables).
The results with A2G00 are fairly consistent with a deficiency in Hex A but not Hex B hav-
ing little to no effect on the degradation of glycans. While on the other hand, Hex B deficiency
leads to accumulation of both glycosphingolipids and glycans. The small increase in A2G00 lev-
els we detected in some of the brain regions we tested could be due to lysosomal dysfunction
brought on by chronic disease which might affect a number of catabolic processes including
glycan degradation. However, the low levels detected in Tay-Sachs sheep compared to Sandh-
off cats suggests that its accumulation is not clinically meaningful in Tay-Sachs disease.
Discussion
GM2 gangliosidoses cause neurodegeneration and early mortality in patients that suffer from
infantile or juvenile onset forms. Therapeutic research is ongoing as there are no currently
approved treatments for these diseases. Mouse models have helped enormously in our under-
standing of GM2 gangliosidoses [3, 25, 35, 45], but their translatability to human patients has
not been established and may be somewhat limited. Naturally occurring large animal models
that better approximate human pathology can provide a better understanding of disease pro-
gression in humans and be a better vehicle for preclinical testing of newly developed
therapeutics.
This paper presents the first longitudinal natural history study of primary and secondary
storage products in large animal models of Sandhoff and Tay-Sachs diseases. Also, this is the
first report of the longitudinal accumulation of a glycan metabolite (A2G00) in a large animal
model of Sandhoff disease. Both lysosomal storage disorders result in a large accumulation of
GM2 ganglioside with marginal accumulation of GA2 ganglioside in the brain of affected ani-
mals. Consequently, they have come to be known as GM2 gangliosidoses. However, a number
of studies have shown that other compounds accumulate in these disorders. For instance, both
Sandhoff and Tay-Sachs show disease-related increases in a biomarker for phospholipidosis,
BMP(22:6) phospholipid, known to be elevated in both GM1 and GM2 gangliosidoses [19]. In
Sandhoff disease, storage of soluble oligosaccharide metabolites results from incomplete degra-
dation of glycan moieties from glycoproteins [14, 36–38]. While BMP(22:6) is a secondary bio-
marker present in elevated levels presumably due to lysosomal dysfunction, both gangliosides
and free glycan limit digestion products are primary biomarkers of this disease, since both pos-
sess a β-linked N-acetylhexosamine at their non-reducing ends which is the catalytic target of
the Hex B enzyme deficient in Sandhoff disease. On the other hand, in Tay-Sachs disease only
Hex A is affected and not Hex B. Therefore, glycans entering the lysosome should be degraded
normally. Thus, only gangliosides and BMP phospholipid accumulate in this type of GM2
gangliosidosis.
For this study, we analyzed gangliosides, a representative oligosaccharide metabolite
A2G00, and BMP phospholipid in a feline model of Sandhoff disease and a ovine model of
Tay-Sachs disease in order to evaluate the effects of disease and age on the accumulation of
these biochemical species. We looked at four matrices, brain, CSF, plasma (in Sandhoff) or
serum (in Tay-Sachs), and urine, at three different time points over the life span of these ani-
mals and compared biomarker levels to those of age-matched unaffected normal controls.
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For the Sandhoff cats, we observed highly elevated levels of GM2 gangliosides and the cor-
responding asialo GA2 gangliosides in the brain (occipital lobe) at all three time points. The
accumulation of GM2 and GA2 did not show signs of reaching a plateau at the last point tested
(four months) suggesting that these disease-related gangliosides could continue to rise if the
animals had lived longer. Very low levels of GM2 and GA2 were detected in wild type age-
matched brain samples at all of the three time points. Low levels of BMP(22:6) were detected
in normal control cats at later time points, while in affected cats BMP(22:6) levels were greatly
elevated compared to controls with increasing accumulation up to 4 months of age.
We detected a number of soluble oligosaccharides in Sandhoff cat brain (occipital lobe) at
all ages tested. These glycan species correspond to limit digestion products that accumulate
due to Hex β-subunit deficiency. Product ion analysis of these species showed them to be
structurally consistent with substrates of Hex B since they contained HexNAc residues at their
non-reducing ends. One of these, A2G00, was chosen as a quantifiable biomarker for this class
of metabolite since a standard for GRIL-LC/MS analysis could be easily generated. A2G00 was
not detected in the occipital lobe, CSF, or plasma of control animals at any age. However, high
levels of this metabolite were detected in Sandhoff cats at all time points tested and A2G00 lev-
els showed significant increase with age in the brain which, like the GM2 and GA2 ganglio-
sides, had not peaked by the last time point. In CSF and plasma, however, A2G00 levels had
peaked by the first time point. The urinary levels of A2G00 were highly elevated in affected ani-
mals, reaching almost 5 μg per ml of urine while remaining at very low levels in unaffected ani-
mals. There was a good correlation between GM2/GA2 and A2G00 levels in the occipital lobe
of affected animals demonstrating the disease-relatedness of this metabolite similar to that of
GM2 and GA2.
For Tay-Sachs sheep, we combined measurements from 7 different brain regions to get the
total brain result. We observed increases in both GM2 and GA2 gangliosides, with GM2 being
the most abundant ganglioside across the three time points tested compared to age-matched
unaffected controls. We observed an age-dependent increase in accumulation by the final time
point, but this was significant for GA2 only. BMP(22:6) was also increased in the Tay-Sachs
sheep compared to age-matched wild type sheep, but the levels plateaued by the first time
point in affected animals.
Surprisingly, we observed a modest but significant amount of A2G00 in Tay-Sachs sheep
brain that was detectable only at the terminal nine-month time point. This was unexpected
since the Hex B enzyme is not compromised in Tay-Sachs disease and lysosomal degradation
of N-glycans should proceed normally. While this accumulation was significant, it was at levels
85-fold less than those detected in Sandhoff cats comparing the occipital lobes from both mod-
els. A possible explanation may be that this low level of accumulation is due to secondary stor-
age of glycan metabolites resulting from lysosomal dysfunction caused by chronic disease in
the Tay-Sachs sheep.
As expected, GM2 and GA2 ganglioside levels were elevated in both Sandhoff cats and Tay-
Sachs sheep. BMP(22:6) phospholipid was also elevated in both disease animals. Comparing
the occipital lobe from affected cats and sheep showed GM2 levels to be 18-fold higher and
GA2 levels 9-fold higher in Sandhoff cats compared to Tay Sachs sheep while BMP(22:6) levels
were comparable. Both ganglioside and BMP phospholipid profiles showed differences among
the 7 regions tested in the Tay-Sachs sheep. For example, at the 9-month time point, GM2 lev-
els were as high as 52.1 ng/μg protein in the temporal lobe and as low as 2.0 ng/μg protein in
the occipital lobe, a difference of 26-fold across brain regions. These differences as well as
those between Sandhoff cats and Tay-Sachs sheep may be due to variations in disease impact
and differences in residual enzyme activity across tissues and species. Previous studies have
shown varying pathology in different brain regions of the Tay-Sachs sheep [43], which may be
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explained by the different accumulation patterns in the brain regions observed in this study.
Overall, the increase in ganglioside accumulation in the brains of these two large animal mod-
els is consistent with progressing pathology of these diseases.
The lack of appreciable oligosaccharide metabolite accumulation in Tay-Sachs, especially
early on in the progression of the disease, is one of the significant differences between Tay-
Sachs and Sandhoff disease. This difference may underpin to some degree the clinical differ-
ences between these two disorders such as the hepatosplenomegaly and bone abnormalities
observed in Sandhoff patients but not in Tay-Sachs.
While we found disease-appropriate changes in these biomarkers, some of our results
showed relatively high standard deviations. This was expected because of the variability of the
response to disease within any population. We made no attempt to reduce the variability by
normalizing analyte measurements to residual β-hexosaminidase enzyme activity but instead
normalized to protein amount or sample volume. For future studies, a comparison could be
made between residual enzyme activity, disease severity and/or biomarker levels.
A related lysosomal metabolic disorder α-mannosidosis exhibits similar symptoms to those
of Sandhoff and Tay-Sachs disease including severe neuropathology. However, unlike these
two GM2 gangliosidoses, α-mannosidosis is characterized by the accumulation of oligosaccha-
rides with glycosphingolipid levels remaining in the normal range [46, 47]. This makes the
accumulation of oligosaccharide metabolites in Sandhoff disease an interesting clinical ques-
tion regarding their possible role in pathogenesis. Determining the importance of oligosaccha-
ride accumulation in Sandhoff disease progression should remain an active area of inquiry
until this is better understood. Any treatment developed for this particular disorder should be
evaluated by its effects on both ganglioside and oligosaccharide metabolite accumulation.
Along these lines, our method for measuring levels of A2G00 may have application in test-
ing biochemical efficacy of new therapeutics. While GM2 and GA2 gangliosides accumulate
mostly in the brain and are challenging to measure in other sample matrices, we saw good cor-
relation between GM2 and GA2 ganglioside accumulation with A2G00 glycan metabolite accu-
mulation in the occipital lobe of Sandhoff cats. We detected significant disease-related
elevation of A2G00 levels in multiple liquid matrices including urine from the same animals
suggesting that this glycan metabolite may be a useful clinical tool since it produces a measur-
able signal in non-invasive sample types. To fully validate a urinary A2G00 assay, a study of
human patients would have to be undertaken in order to explore its limitations and reliability.
Currently, enzyme-replacement therapies [5], gene therapies and substrate reduction therapies
[48] are being studied as possible intervention strategies for GM2 gangliosidoses [49–52]. Uri-
nary A2G00 analysis may help support such efforts.
This natural history study involving two large animal models which mimic GM2 gangliosi-
doses in humans has led to a better understanding of how disease progression influences the
accumulation of pathology-related metabolites. These metabolites are useful for evaluating dis-
ease severity or as pharmacodynamic markers for measuring drug efficacy. The soluble A2G00
metabolite, in the future, may be important in these roles, especially since its levels can be
monitored in an easily accessible sample matrix such as urine. However, there is still much we
don’t understand about what drives the different aspects of these disease. The importance of β-
hexosaminidase substrates in driving disease progression should be explored more fully. These
two large animal models may provide a valuable resource to that end.
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S1 Fig. Tay-Sachs ganglioside levels in different brain regions. Brain samples from Tay-
Sachs (TS) and age-matched unaffected (WT) normal control sheep were provided as frozen
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tested included: (A-B) cerebellum, (C) occipital cortex, (D) temporal lobe, (E) parietal cortex,
(F) corona radiata, and (G) thalamus. Samples for each time point were collected in triplicate
for analysis except as noted in S1 Table. Bars represent GM1 (purple), GA1 (pink), GM2
(blue), GA2 (green), and GM3 (orange) ganglioside levels (means ± SD).
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S2 Fig. Comparison of occipital brain region in Sandhoff and Tay-Sachs for glycolipid,
phospholipid, and glycan biomarkers. Results for Sandhoff (SH, blue bars) and Tay-Sachs
(TS, red bars) occipital lobe biopsies were compared. Three animals for each time point were
analyzed except as indicated in S1 Table. (A) Sandhoff vs. Tay-Sachs GM2 levels. (B) Sandhoff
vs. Tay-Sachs BMP(22:6) levels. (C) Sandhoff vs. Tay-Sachs A2G00 levels. Bars represents
means ± SD.
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S3 Fig. Tay-Sachs BMP levels in 7 different brain regions. BMP(22:6) phospholipid levels
were measured in Tay-Sachs (TS) and age-matched unaffected wild type (WT) normal con-
trols. Brain samples from Tay-Sachs sheep were collected in triplicate for each time point
except as indicated in S1 Table. (A-B) cerebellum, (C) occipital cortex, (D) temporal lobe, (E)
parietal cortex, (F) corona radiata, and (G) thalamus. Bars represent the mean ± SD of BMP
(22:6) levels.
(DOCX)
S4 Fig. Lack of substantial glycan metabolites in Tay-Sachs sheep brain. The extracted ion
current for glycan metabolites in Sandhoff cat (top) and Tay-Sachs sheep (bottom) is shown
along with putative structures and the A2G00 species which was verified by data-dependent
product ion analysis and co-elution with differentially isotope labeled A2G00 standard. Other
than a few oligoglucosides (m/z = 744.28 and 906.33) only very low levels of the types of oligo-
saccharides that are so prominent in Sandhoff cats are found in the Tay-Sachs ovine sample.
Monosaccharides within the oligosaccharides are shown symbolically as follows: glucose (blue
circles), galactose (yellow circles), mannose (green circles), generic hexose (open circles), N-
acetylglucosamine (blue squares), N-acetylgalactosamine (yellow squares), and generic N-acet-
ylhexosamine (open squares). The m/z values for each species along with corresponding puta-
tive structures are shown where they eluted. The ion intensity (relative abundance) for the
Tay-Sachs sample was scaled to that of the Sandhoff sample for easier comparison.
(DOCX)
S5 Fig. A2G00 glycan levels in individual brain regions in Tay-Sachs sheep. A2G00 levels
were measured in Tay-Sachs (TS) and age-matched unaffected wild type (WT) normal con-
trols. Brain samples from Tay-Sachs sheep were collected in triplicate for each time point
except as indicated in S1 Table. (A-B) cerebellum, (C) occipital cortex, (D) temporal lobe, (E)
parietal cortex, (F) corona radiata, and (G) thalamus. Bars represent means ± SD of A2G00 lev-
els in the regions tested.
(DOCX)
S1 Table. Samples analyzed. Brain samples from Sandhoff feline were provided as powdered
brain from a single punch (occipital lobe). Brain samples from Tay-Sachs (TS) sheep were pro-
vided as frozen tissue from seven different brain regions including: cerebellum sample 1 and 2,
occipital lobe, temporal lobe, parietal lobe, corona radiata, and thalamus. Additional samples
taken from each animal included cerebrospinal fluid (CSF), plasma or serum, and urine. Sam-
ples for each time point, sample matrix, and genotype were collected in triplicate except where
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S2 Table. Sandhoff feline analyte measurement results. Quantitative results for each analyte
tested are shown for Sandhoff (SH) and age-matched unaffected (UA) cats at 1, 2, and 4
months of age. The number of animals (n) in each group is shown along with the mean and
standard deviation (SD) and the p-value from one-tailed t-tests. Units are ng/μg protein for
gangliosides, ng/mg protein for BMP phospholipid and A2G00 glycan metabolite except for
urinary A2G00 levels which are expressed as ng/mL of urine.
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S3 Table. Age effect on analyte accumulation in Sandhoff felines. A two-way ANOVA with
Tukey HSD post hoc test was carried out on analyte levels in Sandhoff felines to determine sta-
tistical differences between age groups suggesting different levels of accumulation as a function
of age. The analytes tested, the age comparisons, and the adjusted p values (p�) are shown.
Resulting p-values less than 0.05 are significant.
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S4 Table. Tay-Sachs ovine analyte measurement results. Quantitative results for each analyte
tested are shown for Tay-Sachs (TS) and age-matched unaffected (UA) sheep at 3, 6, and 9
months of age. The number of animals (n) in each group is shown along with the mean and
standard deviation (SD) and the p-value from one-tailed t-tests. Units are ng/μg protein for
gangliosides, ng/mg protein for BMP phospholipid and A2G00 glycan metabolite except for
urinary A2G00 levels which are expressed as ng/mL of urine.
(DOCX)
S5 Table. Age effect on analyte accumulation in Tay-Sachs sheep. A two-way ANOVA with
Tukey HSD post hoc test was carried out on analyte levels in Tay-Sachs ovines to determine
statistical differences between age groups suggesting different levels of accumulation as a func-
tion of age. The analytes tested, the age comparisons, and the adjusted p values (p�) are shown.
Resulting p-values less than 0.05 are significant.
(DOCX)
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